134 related articles for article (PubMed ID: 37806613)
1. Comparing the performance of 2 human papillomavirus assays for a new use indication: a real-world evidence-based evaluation in the United States.
Wheeler CM; Torrez-Martinez NE; Torres-Chavolla E; Parvu V; Andrews JC; Du R; Robertson M; Joste NE; Cuzick J;
Am J Obstet Gynecol; 2024 Feb; 230(2):243.e1-243.e11. PubMed ID: 37806613
[TBL] [Abstract][Full Text] [Related]
2. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
3. Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, ≥25 years of age, with NILM cytology.
Stoler MH; Wright TC; Parvu V; Yanson K; Cooper CK; Andrews J
Gynecol Oncol; 2019 Apr; 153(1):26-33. PubMed ID: 30638767
[TBL] [Abstract][Full Text] [Related]
4. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
5. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
[No Abstract] [Full Text] [Related]
7. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.
El-Zein M; Gotlieb W; Gilbert L; Hemmings R; Behr MA; Franco EL;
Int J Cancer; 2021 Jan; 148(2):492-501. PubMed ID: 32781481
[TBL] [Abstract][Full Text] [Related]
8. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
Tay SK; Lin LE; Goh RC
Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
[TBL] [Abstract][Full Text] [Related]
9. Detection of high-grade cervical neoplasia using extended genotyping: Performance data from the longitudinal phase of the Onclarity trial.
Stoler MH; Wright TC; Parvu V; Yanson K; Cooper CK; Andrews JA
Gynecol Oncol; 2023 Mar; 170():143-152. PubMed ID: 36682092
[TBL] [Abstract][Full Text] [Related]
10. The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.
Wheeler CM; Hunt WC; Cuzick J; Langsfeld E; Robertson M; Castle PE;
Int J Cancer; 2014 Aug; 135(3):624-34. PubMed ID: 24226935
[TBL] [Abstract][Full Text] [Related]
11. Comparison of HPV-positive triage strategies combining extended genotyping with cytology or p16/ki67 dual staining in the Italian NTCC2 study.
Benevolo M; Ronco G; Mancuso P; Carozzi F; De Marco L; Allia E; Bisanzi S; Rizzolo R; Gustinucci D; Del Mistro A; Frayle H; Confortini M; Viti J; Iossa A; Cesarini E; Bulletti S; Passamonti B; Gori S; Toniolo L; Bonvicini L; Venturelli F; Wentzensen N; Giorgi Rossi P;
EBioMedicine; 2024 Jun; 104():105149. PubMed ID: 38759278
[TBL] [Abstract][Full Text] [Related]
12. Risk stratification for cervical precancer and cancer by DH3-HPV partial genotyping and cytology in women attending cervical screening: A retrospective cohort study.
Fu Y; Li Y; Li X; Wang X; Lü W
J Med Virol; 2023 Feb; 95(2):e28482. PubMed ID: 36609841
[TBL] [Abstract][Full Text] [Related]
13. The Onclarity Human Papillomavirus Trial: Design, methods, and baseline results.
Stoler MH; Wright TC; Parvu V; Vaughan L; Yanson K; Eckert K; Karchmer T; Kodsi S; Cooper CK
Gynecol Oncol; 2018 Jun; 149(3):498-505. PubMed ID: 29681462
[TBL] [Abstract][Full Text] [Related]
14. Clinical Performance of the BD Onclarity Extended Genotyping Assay for the Management of Women Positive for Human Papillomavirus in Cervical Cancer Screening.
Volesky KD; Magnan S; Mayrand MH; Isidean SD; El-Zein M; Comète E; Franco EL; Coutlée F
Cancer Epidemiol Biomarkers Prev; 2022 Apr; 31(4):851-857. PubMed ID: 35131879
[TBL] [Abstract][Full Text] [Related]
15. HPV Testing With 16, 18, and 45 Genotyping Stratifies Cancer Risk for Women With Normal Cytology.
Stoler MH; Wright TC; Parvu V; Yanson K; Eckert K; Kodsi S; Cooper C
Am J Clin Pathol; 2019 Mar; 151(4):433-442. PubMed ID: 30649177
[TBL] [Abstract][Full Text] [Related]
16. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.
Kang Y; Sun P; Mao X; Dong B; Ruan G; Chen L
J Gynecol Oncol; 2019 May; 30(3):e29. PubMed ID: 30887754
[TBL] [Abstract][Full Text] [Related]
17. Validation of cobas 4800 HPV assay in SurePath Papanicolaou specimens for cervical cancer screening.
Guo M; Shlyakhova N; Khanna A; Tinnirello AA; Schmeler KM; Hwang J; Sturgis EM; Stewart J
J Am Soc Cytopathol; 2021; 10(4):399-405. PubMed ID: 33967024
[TBL] [Abstract][Full Text] [Related]
18. p16/Ki67 dual stain triage versus cytology in primary human papillomavirus-based cervical cancer screening with limited genotyping.
Trzeszcz M; Mazurec M; Jach R; Mazurec K; Kotkowska-Szeps I; Kania M; Wantuchowicz M; Wasowska J; Duczek-Polakiewicz M; Rozmus P; Streb J; Halon A
J Med Virol; 2023 Nov; 95(11):e29271. PubMed ID: 38009626
[TBL] [Abstract][Full Text] [Related]
19. Triaging HPV-positive women with normal cytology by p16/Ki-67 dual-stained cytology testing: baseline and longitudinal data.
Uijterwaal MH; Polman NJ; Witte BI; van Kemenade FJ; Rijkaart D; Berkhof J; Balfoort-van der Meij GA; Ridder R; Snijders PJ; Meijer CJ
Int J Cancer; 2015 May; 136(10):2361-8. PubMed ID: 25345358
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
